Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin for Central Sensitization in TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing native joint unilateral TKA due to Grade 3-4 primary osteoarthritis~* Patients with score of at least 40 on Central Sensitization Inventory~* Patients who will complete PT within the U of Iowa Health Care system~* Patients who have been nonsmokers for \> 2 years~* Patients between the ages of 50 and 85~Exclusion Criteria:~* Patients already taking pregabalin or had an adverse effect with pregabalin in the past~* Patients indicated for joint revision surgery~* Patients taking at least 30 morphine milligram equivalents per day for the past 1 month~* Patients with an estimate GFR \< 30 ml/min~* Patients who do not have an understanding of English~* Patients who are pregnant or women of child-bearing years~* Patients who are prisoners~* Patients who score \< 40 on the CSI~* Patients who answer Yes to any questions on the Columbia Suicide Severity Rating Scale or express suicidal ideation

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Participants will receive standard peri-operative pain management
- Study (Pregabalin) (Type: EXPERIMENTAL): Participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days. Then Stop.

Based on this trial design, predict the completion outcome and termination type (if applicable).